We explored potential mechanisms whereby CD133 suppresses trametinib-induced apoptosis in order to promote melanoma cell survival, first by CRISPR-Cas9-mediated knockout of CD133 in BAKP melanoma cells. This evidence concerns the gene PROM1 and melanoma.